LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.

Phase 1/Phase 2

Georgetown University

Cedars-Sinai Medical Center
Novartis
University of Texas Southwestern Medical Center
Virginia Mason Hospital/Medical Center

Everolimus
Sirolimus